Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer. Our aim: to transform the lives of patients and families affected by genetic disease.
Recently members of our team toured the Institute for Ophthalmic Research lab in Tübingen, #Germany. Thanks to Dr. Dominik Fischer and his colleagues for sharing some great insight into the important #research taking place at the institute.
The teams from our #SanFrancisco and #Cambridge offices joined together recently at our All Hands Meeting to share best practices with one another, team build, discuss our latest #research and network with fellow colleagues. A great couple of days with a great team!